ADMET and DMPK

Vol 4, No 3 (2016)

Overviews and recent advances in the development of protein kinase inhibitors, Part I.

Guest editor: Godefridus J. Peter

Table of Contents

Editorial

ADME/DMPK in the development and use of tyrosine and serine-threonine kinase inhibitors PDF
Godefridus J. Peters, Kin Tam 182-185

Reviews

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer PDF
Jonathan R. Thompson, Smitha P. Menon, Grace K. Dy 186-211
Cardiovascular safety of tyrosine kinase inhibitors: Putting their “QT-phobia” in perspective PDF
Rashmi Shah 212-231

Original Scientific Articles

Cross talk of c-Jun N-terminal kinase and p38 map kinase modulate insulin and TNFα-stimulated VCAM-1 expression in rat aorta endothelial cells PDF
Gregory B. Pott, Mark Tsurudome, Jamie Bui, Chelsea Gardner, Marc Lee Goalstone 232-240
Dose optimization of ceftriaxone-vancomycin combination using fractional inhibitory concentration kinetics in resistant bacteria PDF
Vishnu Dutt Sharma, Aman Singla, Manu Chaudhary, Mukesh Kumar, Anuj Bhatnagar, Shailesh Kumar, Manish Taneja 241-260
Evaluation of P-glycoprotein expression in pain relevant tissues: understanding translation of efflux from preclinical species to human PDF
Renu Singh Dhanikula, Cyrla Hoffert, Rebecca Grant, Denis Projean, Rosemarie Panetta, Dajan O'Donnell, Marie Roumi 261-268
Evaluation of pharmacokinetic and pharmacodynamic interaction between repaglinide and atazanavir in healthy, diabetic and hepatic impaired rats: possible inhibition of CYP3A, OATP, and P-glycoprotein transporters PDF
Thirumal Eswara Goud, Srinivas Maddi, Nayakanti Devanna, Thatipamula Rajendra Prasad 269-279


ISSN 1848-7718